A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
This is a prospective, single arm phase IIa trial in which patients with early breast cancer
will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart
(maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be
collected at baseline and at surgery. Post-operative treatment will be at the discretion of
Primary objective: to determine if a short course of RANKL inhibition with denosumab can
induce a decrease in tumor proliferation rates as determined by Ki67 immunohistochemistry
(IHC) in newly diagnosed, early stage breast cancer in pre-menopausal women.
- To determine the number of absolute Ki67 responders after a short course of denosumab
(defined as <2.7% IHC staining in the post treatment tumor biopsy).
- To determine the effects of a short course of denosumab on serum C-terminal telopeptide
- To determine the effects of a short course of denosumab on RANK/RANKL gene expression
and signaling as assessed by immunohistochemistry (IHC) and gene expression profile in
- To determine the effect of a short course of denosumab on tumor apoptosis rates using
- To determine the effect of a short course of denosumab on modulating the immature
mammary epithelial cell populations in the tumor.
- To determine the effect of a short course of denosumab on estrogen signaling pathways
in the tumor.
- To determine the effect of a short course of denosumab on various immune - To determine
effect of safety profile of denosumab
Focus of the trial:
Primary Purpose: Treatment
Phase of the trial:
Location of trial:
Royal Melbourne Hospital - Victoria,
-- Contact --
Please contact the recruitment facility